Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: A report from the children's oncology group

Journal of Nuclear Medicine

Volumn 54, Issue 4, 2013, Pages 541-548

  Yanik, Gregory A ^a   Parisi, Marguerite T ^b   Shulkin, Barry L ^c   Naranjo, Arlene ^d   Kreissman, Susan G ^e   London, Wendy B ^f   Villablanca, Judith G ^g   Maris, John M ^h   Park, Julie R ^b   Cohn, Susan L ⁱ   McGrady, Patrick ^d   Matthay, Katherine K ^j  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Bone marrow transplantation; MIBG; Neuroblastoma; Pediatrics

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2 ANTIBODY; ISOTRETINOIN; MELPHALAN; UNCLASSIFIED DRUG; VINCRISTINE;

AGE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CELL CYCLE PARAMETERS; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CURIE SCORE; DISEASE COURSE; EVENT FREE SURVIVAL; FEMALE; GENE; HIGH RISK PATIENT; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; MITOSIS KARYORRHEXIS INDEX; MULTIPLE CYCLE TREATMENT; MYCN GENE; NEUROBLASTOMA; PLOIDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

3-IODOBENZYLGUANIDINE; ANTIBODIES; CHILD; FEMALE; HUMANS; INFANT; IODINE RADIOISOTOPES; MALE; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; RESEARCH REPORT; STEM CELL TRANSPLANTATION;

EID: 84875768440     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.112334     Document Type: Article

References (40)

1. Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer. 1997;33: 2130-2135.
2. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-1173.
3. Kreissman SG, Villablanca JG, Diller L, et al. Response and toxicity to a doseintensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): a Children's Oncology Group (COG A3973) study. J Clin Oncol. 2007; 25:9505.
4. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363: 1324-1334.
5. Wieland DM, Mangner TJ, Inbasekaran MN, et al. Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. J Med Chem. 1984;27:149-155.
6. Sisson JC, Frager MS, Valk TW, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med. 1981;305:12-17.
7. Shapiro B, Copp JE, Sisson JC, et al. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med. 1985;26:576-585.
8. Treuner J, Feine U, Niethammer D, et al. Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet. 1984;1:333-334.
9. Hoefnagel CA, Voute PA, de Kraker J, et al. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med. 1987;28:308-314.
10. Parisi MT, Greene MK, Dykes TM, et al. Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. Invest Radiol. 1992; 27:768-773.
11. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998;39:679-688.
12. Lumbroso JD, Guermazi F, Hartmann O, et al. Meta-iodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans. Prog Clin Biol Res. 1988;271:689-705.
13. Claudiani F, Stimamiglio P, Bertolazzi L, et al. Radioiodinated metaiodobenzylguanidine in the diagnosis of childhood neuroblastoma. Q J Nucl Med. 1995;39:21-24.
14. Ady N, Zucker JM, Asselain B, et al. A new 123I-MIBG whole body scan scoring method: application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer. 1995;31A:256-261.
15. Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol. 2003;21: 2486-2491.
16. Messina JA, Cheng S-C, Franc B, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer. 2006;47:865-874.
17. Perel Y, Conway J, Kletzel M, et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol. 1999;21:13-18.
18. Suc A, Lumbroso J, Rubie H, et al. Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer. 1996;77:805-811.
19. Kushner BH, Yeh SD, Kramer K, et al. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol. 2003;21:1082-1086.
20. Katzenstein HM, Cohn S, Shore R, et al. Scintigraphic response by 123Imetaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol. 2004;22:3909-3915.
21. Schmidt M, Simon T, Hero B, et al. The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma .1 year of age on a highrisk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer. 2008;44:1552-1558.
22. Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol. 1998;16:953-965.
23. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477.
24. Matthay KK, Shulkin B, Ladenstein R, et al. Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010; 102:1319-1326.
25. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-35.
26. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. New York, NY: Oxford University Press; 2003.
27. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Statist. 1958;53:457-481.
28. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35:1-39.
29. Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute Inc.; 1995.
30. NaranjoA, ParisiMT, ShulkinBL, et al. Comparison of 123I- metaiodobenzylguanidine (MIBG) and 131I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011;56:1041-1045.
31. Ladenstein R, Lasset C, Hartmann O, et al. Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation. J Clin Oncol. 1993;11:2330-2341.
32. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:649-658.
33. Frappaz D, Bonneu A, Chauvot P, et al. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group. Med Pediatr Oncol. 2000;34:237-241.
34. Matthay KK, Tan JC, Villablanca JG, et al. Phase I dose escalation of iodine- 131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006;24: 500-506.
35. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131- metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25:1054-1060.
36. Miano M, Garaventa A, Pizzitola MR, et al. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant. 2001;27:571-574.
37. de Kraker J, Hoefnagel KA, Verschuur AC, et al. Iodine-131- metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer. 2008;44:551-556.
38. Gaze MN, Chang YC, Flux GD, et al. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm. 2005;20:195-199.
39. DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol. 2008;35(suppl 1):S35-S48.
40. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol. 2002;20:2142-2149.